Enhanced expression and activity of DNA polymerase β in chronic myelogenous leukemia

• Published in: Anticancer research 2006-01, Vol.26 (1B), p.523-525
• Main Authors: CANITROT, Yvan, LAURENT, Guy, ASTARIE-DEQUEKER, Catherine, BORDIER, Christine, CAZAUX, Christophe, HOFFMANN, Jean-Sébastien
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Blotting, Western; DNA Polymerase beta - biosynthesis; DNA Polymerase beta - blood; Hematologic and hematopoietic diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Neutrophils - enzymology; Tumors
• ISSN: 0250-7005; 1791-7530

Chronic myelogenous leukemia (CML) is characterized by an initial chronic phase that invariably evolves to the more aggressive phase of blast crisis. Although the determinants of this transition are still unknown, it has been shown that the blast crisis is accompanied by genetic instability. The expression and activity of the error-prone DNA polymerase beta (pol beta) were investigated in blood samples from CML patients, by Western blotting and by an in vitro replication assay, respectively. Pol beta expression and activity were significantly higher in CML samples compared to those of healthy donors. Our results suggest that the excess of pol beta in CML could contribute to the genetic instability observed during the evolution of the disease from the chronic phase to blast crisis.